Twist Bioscience Corp
TWST31.850USD
+0.780+2.51%
Handelsschluss 10/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.92BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Twist Bioscience Corp Unternehmen
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
Twist Bioscience Corp Informationen
BörsenkürzelTWST
Name des UnternehmensTwist Bioscience Corp
IPO-datumOct 31, 2018
CEODr. Emily M. Leproust, Ph.D.
Anzahl der mitarbeiter923
WertpapierartOrdinary Share
GeschäftsjahresendeOct 31
Addresse681 Gateway Blvd.
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94080
Telefon18007190671
Websitehttps://www.twistbioscience.com/
BörsenkürzelTWST
IPO-datumOct 31, 2018
CEODr. Emily M. Leproust, Ph.D.
Führungskräfte von Twist Bioscience Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
328.92K
-1.19%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
108.58K
-4.43%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
48.13K
-1.22%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
44.01K
-2.63%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
12.60K
+55.04%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
7.34K
-11.12%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
328.92K
-1.19%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
108.58K
-4.43%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
48.13K
-1.22%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
44.01K
-2.63%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Umsatzaufteilung
Währung: USDAktualisiert: 7 hours ago
Währung: USDAktualisiert: 7 hours ago
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%
Nach RegionUSD
Name
Umsatz
Anteil
Americas
59.39M
61.82%
EMEA
30.74M
32.00%
APAC
5.93M
6.17%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%
Aktionärsstatistik
Aktualisiert: Wed, Aug 20
Aktualisiert: Wed, Aug 20
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
ARK Investment Management LLC
10.60%
The Vanguard Group, Inc.
9.64%
Artisan Partners Limited Partnership
8.38%
BlackRock Institutional Trust Company, N.A.
8.05%
William Blair Investment Management, LLC
6.47%
Andere
56.85%
Aktionäre
Aktionäre
Anteil
ARK Investment Management LLC
10.60%
The Vanguard Group, Inc.
9.64%
Artisan Partners Limited Partnership
8.38%
BlackRock Institutional Trust Company, N.A.
8.05%
William Blair Investment Management, LLC
6.47%
Andere
56.85%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
59.87%
Investment Advisor/Hedge Fund
36.46%
Hedge Fund
12.53%
Research Firm
5.06%
Individual Investor
1.94%
Pension Fund
1.48%
Bank and Trust
0.41%
Family Office
0.18%
Insurance Company
0.07%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
562
70.01M
115.98%
-1.97M
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
ARK Investment Management LLC
6.40M
10.6%
+158.85K
+2.54%
Jun 30, 2025
The Vanguard Group, Inc.
5.82M
9.64%
-36.15K
-0.62%
Jun 30, 2025
Artisan Partners Limited Partnership
5.06M
8.38%
-790.34K
-13.51%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.86M
8.05%
+226.25K
+4.89%
Jun 30, 2025
William Blair Investment Management, LLC
3.91M
6.47%
+99.74K
+2.62%
Jun 30, 2025
State Street Global Advisors (US)
2.50M
4.14%
-192.68K
-7.15%
Jun 30, 2025
EdgePoint Investment Group Inc.
2.39M
3.95%
+1.27M
+114.33%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.30M
3.81%
-116.36K
-4.82%
Jun 30, 2025
Invesco Advisers, Inc.
2.29M
3.8%
-1.04M
-31.23%
Jun 30, 2025
Point72 Asset Management, L.P.
2.16M
3.58%
+725.54K
+50.64%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 16 hours ago
Aktualisiert: 16 hours ago
Name
Anteil
ARK Genomic Revolution ETF
5.62%
iShares Genomics Immunology and Healthcare ETF
3.42%
Global X Genomics & Biotechnology ETF
1.81%
WisdomTree BioRevolution Fund
1.65%
ARK Innovation ETF
1.4%
Franklin Genomic Advancements ETF
1.21%
ROBO Global Healthcare Technology & Innovation ETF
1.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.54%
SPDR S&P Biotech ETF
0.49%
JPMorgan Fundamental Data Science Small Core ETF
0.34%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil5.62%
iShares Genomics Immunology and Healthcare ETF
Anteil3.42%
Global X Genomics & Biotechnology ETF
Anteil1.81%
WisdomTree BioRevolution Fund
Anteil1.65%
ARK Innovation ETF
Anteil1.4%
Franklin Genomic Advancements ETF
Anteil1.21%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil0.54%
SPDR S&P Biotech ETF
Anteil0.49%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.34%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
